Archives
-
Cycloheximide in Viral Protein Turnover Studies
2026-09-02
Cycloheximide is more than a protein biosynthesis inhibitor: used as a timed perturbation, it can help separate translation-dependent effects from phosphorylation-driven viral trafficking. This guide applies that logic to influenza NEP and vRNP nuclear export while defining practical assay controls and limitations.
-
PPT: A Causal Assay Framework for ERα Research
2026-09-02
PPT (Propyl Pyrazole Triol) enables selective interrogation of ERα biology. This guide connects its receptor pharmacology with the FOXM1–ERα axis in female lung adenocarcinoma and translates that evidence into better assay design.
-
JC-1 Mitochondrial Membrane Potential Assay Kit Guide
2026-09-01
Learn how the JC-1 Mitochondrial Membrane Potential Assay Kit connects ΔΨm measurements with apoptosis research and immunogenic cell death studies. This guide emphasizes mechanism-based controls, interpretation limits, and assay decisions inspired by recent tumor-immunity research.
-
EZ Cap™ EGFP mRNA (5-moUTP) Assay Guide
2026-09-01
A scenario-based guide to using EZ Cap™ EGFP mRNA (5-moUTP), SKU R1016, as an orthogonal reporter in cell viability, proliferation, cytotoxicity, and translation studies. It connects cap structure, 5-moUTP modification, transcript handling, delivery variables, and data interpretation without treating EGFP fluorescence as a substitute for direct viability measurements.
-
Palomid 529 (P529) in Cancer Research
2026-08-31
Palomid 529 (P529) provides a practical way to interrogate mTORC1/mTORC2 signaling in tumor-cell survival, angiogenesis, cisplatin resistance, and radiotherapy response. This workflow connects the RCN2–PPP2CA–PI3K-AKT mechanism in esophageal squamous cell carcinoma with experimentally testable pharmacology while emphasizing controls for solubility, timing, and combination effects.
-
Cefotaxime for Antimicrobial Resistance Research
2026-08-31
Cefotaxime gives researchers a practical phenotypic readout for connecting beta-lactam activity with resistance-gene carriage, plasmid mobility, and isolate behavior. This workflow extends hospital surveillance findings into reproducible susceptibility panels, bacterial infection models, and troubleshooting strategies without treating an in vitro MIC as a clinical conclusion.
-
Ruxolitinib Phosphate: From JAK Signals to Cell Fate
2026-08-30
A translational perspective on how Ruxolitinib phosphate and INCB018424 can be used to connect JAK1/2 inhibition with STAT3-dependent mitochondrial remodeling, apoptosis, and pyroptosis in anaplastic thyroid carcinoma research.
-
E-64d Workflows for Calpain and Cell-Death Research
2026-08-29
E-64d combines intracellular access with irreversible cysteine protease inhibition, making it useful for platelet, apoptosis, neuronal, and cancer research workflows. This guide pairs practical dosing and handling strategies with time-resolved assay design inspired by MEDUSA, helping researchers distinguish genuine cell death from slower growth.
-
4-Phenylbutyric Acid: ER Stress Workflow
2026-08-28
Build a solvent-controlled 4-PBA workflow for separating endoplasmic reticulum stress from ferroptosis in HK-2 kidney injury models. This guide translates PFOS-response data into practical treatment groups, assay timing, formulation controls, and troubleshooting decisions.
-
Arrb2–6-ketoLCA Axis in Hepatic Ischemia–Reperfusion
2026-08-28
The reference study identifies hepatocyte Arrb2 as a regulator of liver ischemia–reperfusion injury through a metabolite-mediated pathway involving 6-ketoLCA and M2 macrophage polarization. Its combination of clinical association analysis, hepatocyte-specific mouse modeling, hypoxia–reoxygenation experiments, and metabolomics provides a useful framework for studying hepatocyte–macrophage communication in transplantation-related inflammation.
-
4-Phenylbutyric Acid in ER Stress Assays
2026-08-27
4-PBA provides a practical rescue strategy for testing whether ER stress drives cancer-cell death, rather than merely correlating with it. This workflow combines chemical chaperone treatment with viability, autophagy, and pathway-specific controls to improve causal interpretation.
-
FOXM1 and ERα in Female Lung Adenocarcinoma
2026-08-27
This preprint integrates transcriptomic, survival, immune, and in vitro analyses to investigate FOXM1 in female lung adenocarcinoma (LUAD). Its proposed FOXM1–miR-204-5p–ERα network offers a mechanistic framework for biomarker discovery, while the partial validation of the ceRNA model highlights important limitations for follow-up studies.
-
MK-1775: Measuring Checkpoint Abrogation
2026-08-26
MK-1775, a selective Wee1 kinase inhibitor, can produce growth arrest and cell killing that are not captured equally by a single viability endpoint. This guide applies a quantitative assay framework to distinguish G2 checkpoint abrogation, DNA damage response inhibition, and true cytotoxicity in cancer research.
-
Entinostat (MS-275) Workflows for Cancer Research
2026-08-26
Entinostat (MS-275) enables selective class I HDAC probing alongside separate measurements of growth arrest and cell death. This guide turns that distinction into practical dose-response, chromatin, retinoblastoma, and translational workflows with troubleshooting built in.
-
Tunicamycin: Designing Better ER Stress Assays
2026-08-25
Tunicamycin is a powerful N-glycosylation inhibitor, but its value depends on separating glycoprotein-processing stress from inflammatory signaling. This guide translates endothelial UPR research into better-controlled macrophage and cell-based assay designs.